Nanobiotix/$NBTX

NBTX jumps after reporting first Phase 1 esophageal cancer data showing 85% disease control and 69% ORR for NBTXR3 at ASTRO 2025.
8 hours agoLightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Nanobiotix

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Ticker

$NBTX
Sector
Primary listing

Employees

103

Nanobiotix Metrics

BasicAdvanced
$1B
-
-$1.27
1.64
-

What the Analysts think about Nanobiotix

Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.

Bulls say / Bears say

An amendment to Nanobiotix’s global licensing agreement with Janssen Pharmaceutica NV in March 2025 shifts nearly all remaining Phase 3 trial costs to J&J, extending its cash runway into mid-2026 and significantly reducing R&D burn (Nasdaq)
The company dosed the first patient in its JNJ-1900 (NBTXR3) CONVERGE Phase 2 trial for Stage 3 unresectable non-small cell lung cancer in January 2025, demonstrating progress in expanding its clinical pipeline in collaboration with J&J (BioSpace)
Early Phase 1 data presented in March 2025 for NSCLC re-irradiation showed favorable safety, injection feasibility, and encouraging efficacy signals with 12-month LPFS of 64% and OS of 83%, underpinning NBTXR3’s therapeutic potential (BioSpace)
Despite extending cash visibility to mid-2026, Nanobiotix’s €28.8 million cash balance as of June 30, 2025 is forecast to be insufficient to fund operations beyond the next twelve months, creating material uncertainty around its going concern status (SEC)
Nanobiotix remains heavily reliant on its amended partnership with Johnson & Johnson and potential non-dilutive financing to sustain development of NBTXR3, exposing the company to significant funding risk if external support diminishes (BioSpace)
NBTXR3 has yet to secure regulatory approval beyond a European CE mark in soft tissue sarcoma, and its commercial viability hinges on successful Phase 3 outcomes and FDA/EMA clearances, which carry inherent trial and approval risks (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

Nanobiotix Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Nanobiotix Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NBTX

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs